Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
.11 and Up!
»
CTIX -- Cellceutix Corporation
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by moogoo gaipan: [QB] CTIX's approach to drug-resistant cancer: Excellent results in animal model experiments in drug-resistant cancers Kevetrin, our lead product candidate, is a small molecule compound proprietary to the Company. Its structure is distinct from other anti-cancer agents currently on the market. Kevetrin was discovered by the Company's founder, Dr. Krishna Menon, and has been studied extensively (in vitro and in vivo) demonstrating potent anti-cancer activity against various cancer cell lines. Kevetrin's recent success in a series of animal model experiments with drug-resistant cancer cell lines, has galvanized the Company to focus on Kevetrin's development potential in this area. Kevetrin's primary mechanism of action is as an AKT inhibitor but it also acts as an alkylating agent and LTB4 inhibitor with anti-angiogenic properties. Some highlights of the studies conducted to date include: * Small molecule drug that is structurally different from anti-cancer agents currently on the market * Primary mechanism of action is AKT inhibition * Potent in vitro cytotoxicity against a panel of human tumor cell lines * Demonstrated success in more than 5,000 small animal tests, achieving significant delays in tumor growth compared to controls in breast, prostate and colon cancer tumors. * In animal tests of a head and neck cancer cell line, delay in tumor growth was significantly increased by 14 days with Kevetrin alone (about the same as with radiation alone) but when Kevetrin was administered in conjunction with radiation, tumor growth delay increased by 36 days, more than two-fold compared to controls * In small animal tests, Kevetrin was well tolerated. We are now conducting additional studies to allow us to request permission from FDA to begin studies in humans. Interesting article and alternate source on the subject: [URL=http://www.cosmosmagazine.com/news/2834/killer-minicells-fight-drug-resistant-cancer]http://www.cosmosmagazine.com/news/2834/killer-minicells-fight-drug-resistant-ca ncer[/URL] [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2